Fig. 6.
The effects of the mGluR2/3 antagonist LY341495 (3 mg/kg) in combination with NAAG (500 μg/10 μl) on MDPV (2 mg/kg) place preference. Data (n = 13–15 per group) are shown as a difference score (difference in time spent in the less-preferred compartment between post-test and pre-test). The significant inhibitory action of NAAG on MDPV-induced CPP (p < 0.01) was blocked by pretreatment with LY341495 (p < 0.05). Data are presented as mean + S.E.M. **p < 0.01, *p < 0.05. SAL, saline; VEH, vehicle; LY, LY341495